IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDx Reports Third Quarter 2026 Results and Provides Corporate Update ● Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information ● Initiated enrollment into GALACTIC registry study from UCLA Medical Center ● Reven
How this was made
The 30-second read
Why it matters
The most tradable elements are the FDA review mechanics (additional information request, paused clock, expected complete response submission before Jan 21, 2027) and early commercialization signals (GALACTIC enrollment at UCLA, expected build in GraftAssureCore revenue, and commercial preparedness for a potential launch).
Market read
This is a company-specific regulatory and operating update that can change expectations for the timing and credibility of FDA authorization and near-term revenue trajectory.
What to watch
The filing emphasizes expected processes and enrollment growth, but it does not quantify future revenue ramp or the probability/timing of authorization beyond the response deadline, leaving valuation sensitive to execution risk.
Pre-revenue diagnostics company reports Q3 2026 revenue of $559,000, GAAP net loss of $3.6 million driven by a $4.1 million contingent consideration gain, and cash of $11.8 million as FDA review continues
Operating spend fell sharply and non-GAAP operating expenses declined 15% sequentially, but revenue remains minimal, cash fell to $11.8 million from $18.7 million in the prior quarter, free cash flow was about negative $7.3 million, and the GAAP net loss benefited from a non-cash fair value gain.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net revenue, Q3 2026GAAP | $559,000 | – | – |
| Net revenue, nine months 2026GAAP | $830K | – | – |
| Cost of revenues, Q3 2026GAAP | $139K | – | – |
| Cost of revenues, nine months 2026GAAP | $238K | – | – |
| Gross profit, Q3 2026GAAP | $420,000 | – | – |
| Gross profit, nine months 2026GAAP | $592K | – | – |
| Gross margin, Q3 2026GAAP | 75.1% | – | – |
| Research-use-only kit sales, Q3 2026GAAP | $21,000 | – | – |
| Research and development expenses, Q3 2026GAAP | $3.79M | decreased 15% sequentially, or by about $693,000 | – |
| Research and development expenses, nine months 2026GAAP | $13.23M | – | – |
| Sales and marketing expenses, Q3 2026GAAP | $1.61M | decreased $309,000 sequentially | – |
| Sales and marketing expenses, nine months 2026GAAP | $5.92M | – | – |
| General and administrative expenses, Q3 2026GAAP | $2.79M | fell slightly sequentially | – |
| General and administrative expenses, nine months 2026GAAP | $8.65M | – | – |
| Change in fair value of contingent consideration, Q3 2026GAAP | −$4.09M | – | – |
| Change in fair value of contingent consideration, nine months 2026GAAP | −$7.72M | – | – |
| Total operating expenses, Q3 2026GAAP | $4.10M | – | – |
| Total operating expenses, nine months 2026GAAP | $20.08M | – | – |
| Loss from operations, Q3 2026GAAP | −$3.68M | – | – |
| Loss from operations, nine months 2026GAAP | −$19.49M | – | – |
| Interest expense, Q3 2026GAAP | −$17K | – | – |
| Other income, net, Q3 2026GAAP | $114K | – | – |
| Net loss, Q3 2026GAAP | −$3.58M | – | – |
| Net loss, nine months 2026GAAP | −$19.13M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.10) | – | – |
| Net loss per share, basic and diluted, nine months 2026GAAP | $(0.53) | – | – |
| Non-GAAP net loss, Q3 2026non-GAAP | −$6.85M | – | – |
| Non-GAAP net loss per share, Q3 2026non-GAAP | $(0.19) | – | – |
| Non-GAAP operating expenses, Q3 2026non-GAAP | $6.74M | decreased 15% sequentially (company description) | flat year over year (company description) |
| Adjusted EBITDA loss, Q3 2026non-GAAP | −$6.30M | – | – |
| Net cash used in operating activities, Q3 2026GAAP | −$6.43M | – | – |
| Net cash used in operating activities, nine months 2026GAAP | −$23.34M | – | – |
| Machinery and equipment purchases and construction in progress, Q3 2026GAAP | −$841K | – | – |
| Machinery and equipment purchases and construction in progress, nine months 2026GAAP | −$2.23M | – | – |
| Free cash flow (non-GAAP), Q3 2026non-GAAP | approximately $(7.3) million negative | – | – |
| Cash, cash equivalents and restricted cash, end of periodGAAP | $11.81M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Laboratory services (CLIA laboratory, Tennessee)The company states most Q3 2026 revenue came from laboratory services performed at its CLIA laboratory in Tennessee, at the request of select clients. | Not separately quantified; described as most of $559,000 | – | – |
| Research-use-only kit salesThe company sold $21,000 in research-use-only kits in the quarter, compared to zero in Q3 2025. It states it does not expect material kitted product revenue until regulatory authorization of GraftAssureDx. | $21,000 | – | – |
Q4 2026 outlook
- NoteTargets outgoing free cash flow of approximately $8 million in the fourth quarter
- NoteExpects sample collection and GraftAssureCore testing revenue to build over the coming months as GALACTIC enrollment grows and additional sites are activated (no figure given)
- NoteExpects to submit its complete FDA response before the January 21, 2027 deadline (no figure given)
Capital returns
- No share repurchases or dividends are reported in the filing.
- Financing in the nine months 2026 includes proceeds from sale of common shares of $26,024 thousand (nine months 2025: $29,143 thousand) and financing costs of $(1,379) thousand (nine months 2025: $(487) thousand).
- Common shares issued and outstanding rose to 32,755 thousand at September 30, 2026 from 28,683 thousand at December 31, 2025. Weighted average shares were 36,863 thousand in Q3 2026 (Q3 2025: 32,033 thousand), including 4.1 million unexercised pre-funded warrant shares.
- The company states it remains thoughtful about capital allocation, hiring and expense growth, and plans to scale its commercial organization prudently.
What drove it
- The company attributes the sequential decline in non-GAAP operating expenses to the winding down of costs associated with the GraftAssureDx FDA submission.
- The company attributes the sequential decline in R&D to lower consulting, software development, and clinical trial and registry service fees tied to the FDA submission.
- The company attributes the sequential decrease in sales and marketing expenses to conference timing and a $110,000 health economics research grant made in the second quarter that did not repeat.
- The company says the improvement in the GAAP net loss was largely driven by a non-cash gain of $4.1 million from the change in fair value of contingent consideration.
- The company says the sequential improvement in Adjusted EBITDA loss represented cost discipline and higher gross profit.
- FDA review: the company received an additional information request in late July 2026. It states the request relates primarily to the design and analysis of the clinical validation study, and that FDA's preliminary view is that the submitted clinical data do not yet support the proposed intended use. The review clock is paused, and the company estimates about half of the review days remain.
- The company expects two external processes, an independent accuracy and repeatability study and a biopsy slide pathology review, to be completed before year end.
- Commercial preparation: Donnie Purto was appointed Senior Vice President of Sales on October 14, 2026. The company describes ongoing work on connectivity for send-out testing, and expanded reimbursement support beyond MolDX-covered jurisdictions.
- GALACTIC registry: enrollment has started at UCLA Medical Center. The company expects GraftAssureCore sample collection and testing revenue to build as enrollment grows and more sites are activated.
Concerns
- Revenue remains minimal at $559,000 in Q3 2026 and the company describes itself as essentially pre-revenue while it awaits potential FDA authorization.
- Cash and cash equivalents and restricted cash fell to $11,814 thousand from $18.7 million at the end of Q2 2026. The company targets about $8 million of outgoing free cash flow in Q4 2026.
- The GAAP net loss of $(3,579) thousand is much smaller than the non-GAAP net loss of $(6,848) thousand, and the company names the fair value gain as the main reason for the narrowing.
- The FDA's preliminary view is that the submitted clinical data do not yet support the proposed intended use. The company's risk factors name the risk that FDA may not grant marketing authorization on the expected timeline or at all.
- The company's risk factors name its limited revenue and history of losses, its need for additional capital, and its ability to continue as a going concern.
- Total liabilities exceed total assets, and the shareholders' deficit was $(24,176) thousand at September 30, 2026.
What to watch
- Submission of the complete FDA response before the January 21, 2027 deadline, and whether FDA restarts the review clock.
- Completion of the independent accuracy and repeatability study and the biopsy slide pathology review, which the company expects before year end.
- Free cash flow against the approximately $8 million outgoing target for Q4 2026, and cash balance versus the $11,814 thousand reported at quarter end.
- GraftAssureCore revenue as GALACTIC enrollment grows and additional sites are activated. No revenue figure has been given.
- Non-GAAP operating expenses after the FDA-submission costs wind down, and any scaling of the commercial organization as the company says it will expand headcount only as revenue growth and adoption justify.
- Movements in the contingent consideration liability, which stood at $35,329 thousand noncurrent at September 30, 2026, and which drive the non-cash fair value line in GAAP operating expenses.
- Reimbursement progress beyond MolDX-covered jurisdictions, and the launch timing of in-house testing at U.S. transplant centers that the company says are targeting 2027.
Balance sheet and cash flow
- Cash and cash equivalents were $11,024 thousand at September 30, 2026 versus $11,583 thousand at December 31, 2025.
- Total assets were $21,742 thousand at September 30, 2026 versus $25,756 thousand at December 31, 2025.
- Total liabilities were $45,918 thousand at September 30, 2026 versus $57,220 thousand at December 31, 2025. Contingent consideration liabilities, noncurrent, were $35,329 thousand versus $43,455 thousand.
- Total shareholders' deficit was $(24,176) thousand at September 30, 2026 versus $(31,464) thousand at December 31, 2025.
- Equipment financing was $82 thousand current and $497 thousand noncurrent at September 30, 2026, following equipment financing proceeds of $609 thousand in Q3 2026.
- Net cash used in operating activities of $(6,433) thousand and capital expenditures of $(841) thousand gave free cash flow of approximately $(7.3) million in Q3 2026. The company says this compares with its prior expectation of $8 million of outgoing free cash flow for the quarter.
- The company attributes the improvement in free cash flow to lower core operating expenses in the quarter and to working capital timing tied to specific second-quarter payments, including vendor payments.
Analysis
Insight Molecular Diagnostics reported Q3 2026 revenue of $559,000, compared with approximately $260,000 in Q3 2025, and gross profit of $420,000 at a 75.1% gross margin (Q3 2025: 53.5%). The company describes its revenue as mostly laboratory services from its Tennessee CLIA lab, with $21,000 of research-use-only kit sales. It states that it remains essentially pre-revenue and does not expect material kit revenue until GraftAssureDx receives FDA authorization. Nine-month revenue was $830 thousand against $2,916 thousand a year earlier, so the revenue base is small and has declined over the period.
Operating spend fell sharply. Total GAAP operating expenses were $4,096 thousand, against $11,187 thousand in Q3 2025 and $11,559 thousand in Q2 2026. The GAAP figure includes a $(4,089) thousand change in fair value of contingent consideration, which is a gain. Non-GAAP operating expenses were $6,742 thousand, flat with $6,725 thousand in Q3 2025 and down from $7,973 thousand in Q2 2026. The company attributes the sequential decline to the wind-down of FDA-submission costs, mainly in R&D, which was $3,793 thousand against $4.5 million in Q2 2026. Sales and marketing rose year over year to $1,607 thousand from $1,386 thousand, and the company is preparing for a launch. General and administrative expenses were $2,785 thousand.
The GAAP net loss of $(3,579) thousand, or $(0.10) per share, compares with $(10,854) thousand, or $(0.34) per share, in Q3 2025. The company names the non-cash fair value gain as the main driver of the narrower loss. On a non-GAAP basis the net loss was $(6,848) thousand, or $(0.19) per share, against $(6,955) thousand, or $(0.22), a year earlier. Adjusted EBITDA loss was $(6,303) thousand against $(7,792) thousand in Q2 2026. Weighted average shares rose to 36,863 thousand from 32,033 thousand, reflecting share sales in the prior twelve months.
Cash is the central constraint. Cash, cash equivalents and restricted cash fell to $11,814 thousand from $18.7 million at the end of Q2 2026 and $20.2 million a year earlier. Net cash used in operating activities was $(6,433) thousand in the quarter and free cash flow was approximately $(7.3) million, which the company compares with its prior expectation of about $8 million of outgoing cash for the quarter. The company targets about $8 million of outgoing free cash flow in Q4 2026. The balance sheet shows a shareholders' deficit of $(24,176) thousand, with contingent consideration liabilities of $35,329 thousand noncurrent.
Regulatory progress is the key item. The FDA's late-July additional information request focused on the clinical validation study design and analysis, and the FDA's preliminary view is that the submitted data do not yet support the proposed intended use. The company expects to submit its full response before January 21, 2027, after two external processes that it expects to finish before year end. The review clock is paused, with about half of the 150-day review days remaining according to the company. The filing gives no revenue or margin guidance beyond the Q4 free cash flow target and qualitative statements on GraftAssureCore revenue.
Not in the filing
stated, not guessed- Q2 2026 net revenue was not printed in the filing; the sequential revenue change cannot be shown.
- Percentage change in revenue year over year was not printed.
- Q2 2026 gross profit and gross margin were not printed.
- Q2 2026 cost of revenues was not printed.
- Q2 2026 loss from operations and total other income were not printed.
- Q2 2026 other income, net and interest expense: Q2 2026 values were taken only from the non-GAAP reconciliation; Q2 2026 total other income, net was not printed.
- Q2 2026 operating cash flow and capital expenditures were not printed in the statements; only Q3 2026 and nine-month figures were given.
- Free cash flow for Q3 2025 and for the nine months of 2026 and 2025 was not printed.
- Prior-year and prior-quarter percentage changes for R&D, sales and marketing, and G&A were not printed as percentages in the filing.
- Quantified GraftAssureCore or laboratory services revenue split was not printed.
- Revenue from GALACTIC registry enrollment was not quantified.
- Prior guidance was not provided, so no comparison with previous outlook is possible.
- Share price reaction and analyst consensus were not provided and are not included.
- Named executive quotes were not present; the letter is signed by IMDx management without individual attribution.
- Non-GAAP reconciliation for nine months was not printed.
- Cash and cash equivalents Q2 2026 balance sheet figure was not printed; the $18.7 million figure refers to cash, cash equivalents and restricted cash.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
IMDx furnished an 8-K with Q3 2026 results and a corporate update focused on its FDA de novo review for GraftAssureDx and the start of patient enrollment in its GALACTIC registry study.
Ticker impact
IMDx reports Q3 2026 results and updates its FDA de novo review for GraftAssureDx, including an additional-information request and expected response timing.
Shares likely face upward bias as investors price improved regulatory momentum and growing in-house testing revenue tied to GALACTIC enrollment.
The filing discloses a concrete FDA process update (additional information request, paused clock, expected submission before Jan 21, 2027) and provides a Q3 revenue datapoint ($559,000) alongside expense wind-down language, which can shift expectations for regulatory and commercial milestones.
Market effects
Could reinforce investor focus on decentralized dd-cfDNA transplant testing and the de novo FDA pathway for lab-developed-to-kitted diagnostics.
Primarily U.S.-focused given FDA de novo review and MolDX reimbursement discussion.
International transplant adoption narrative (U.S., Europe, Asia feedback) may support broader sentiment toward transplant diagnostics, though the regulatory catalyst is U.S.-specific.
Counterpoint
Regulatory uncertainty remains because FDA preliminarily viewed the submitted clinical data as not yet supporting the proposed intended use, so the next submission could still face further requests.
Key entities
- issuerInsight Molecular Diagnostics Inc.
Nasdaq-listed company reporting Q3 2026 results and providing an FDA and commercialization update for GraftAssureDx.
- productGraftAssureDx
IMDx dd-cfDNA kidney transplant rejection test under FDA de novo review.
- regulatorFDA
Requested additional information in late July, pausing the review clock, and provided feedback for the response approach.
- clinical_programGALACTIC registry study
Registry study with enrollment initiated at UCLA Medical Center, intended to support sample collection and related testing revenue.
- reimbursement_programMolDX
Local coverage determination revision discussed as improving the reimbursement environment for surveillance testing.
